Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests.

Published

Journal Article

Pharmacogenomic tests offer a promising strategy to improve the safety and efficacy of drug treatment. Compelling examples, such as HLA-B*5701 testing to identify patients at risk for abacavir-associated hypersensitivity, are already changing clinical care. However, the level of evidence required to establish clinical utility is often the subject of debate. Determining the most efficient and effective pathway to benefit for a given test is therefore both a practical and an ethical concern.

Full Text

Duke Authors

Cited Authors

  • Haga, SB; Burke, W

Published Date

  • July 2011

Published In

Volume / Issue

  • 90 / 1

Start / End Page

  • 25 - 27

PubMed ID

  • 21691271

Pubmed Central ID

  • 21691271

Electronic International Standard Serial Number (EISSN)

  • 1532-6535

Digital Object Identifier (DOI)

  • 10.1038/clpt.2011.71

Language

  • eng

Conference Location

  • United States